Journal of Neuro-Oncology and Neuroscience Open Access

  • ISSN: 2572-0376
  • Journal h-index: 5
  • Journal CiteScore: 0.38
  • Journal Impact Factor: 0.36
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days

David Fortin

David Fortin
Director of the level for multidisciplinary neuro-oncology, Surgery, Université de Sherbrooke, Canada

Biography

EDUCATION : 1998-1999 1997-1998 1991-1997 1987-1991 Clinical and research fellowship in neuro-oncology, Oregon Health Sciences University, Portland, Oregon. Fellow in neuro-oncology (OHSU) Neuro-oncology certificate, university of Western Ontario, London, Canada Neurosurgery training, Université de Sherbrooke, Sherbrooke, Canada MD, medical school, Université de Sherbrooke, Sherbrooke, Canada Membership on Grant Panels 2009-Reviewer for Expert opinion on drug delivery, Current progress in drug research, Journal of clinical anesthesia, cancer, Brain research bulletin 2006-Editorial board of the Canadian Journal of Neurosciences Professionnal Work 2011-Director of the level 4 multidisciplinary neuro-oncology, Surgery, Université de Sherbrooke, Canada 2007-2011-Director of Neurosurgery Department, Surgery/Faculty of Medicine, Université de Sherbrooke, Canada Honours 2006-2011Chair of the Neurosurgery division, Department of surgery, Université de Sherbrooke National bank research chair on brain tumors, Banque nationale du Canada 2005-2009César Galéano annual award : Best medical school professor, Medical school, Université de Sherbrooke PUBLICATIONS : 1. Fortin D, Morin PA, Belzile F, Mathieu D, Paré FM. (2014) Intra-arterial carboplatin as a salvage strategy in the treatment of recurrent glioblastoma multiforme. J Neurooncol. 119(2):397-403. 2. Whittingstall K, Bernier M, Houde JC, Fortin D, Descoteaux M. (2014) Structural pathways underlying visuospatial processing in humans. Cortex. 56:85-98. 3. Roy LO, Poirier MB, Fortin D. Transforming growth factor-beta and its implication in the malignancy of gliomas. Target Oncol. Accepted on Feb 2014 : DOI 10.1007/s11523-014-0308-y. 4. Blanchette M, Tremblay L, Lepage M, Fortin D. (2014) Impact of Drug Size on Brain Tumor and Brain Parenchyma Delivery following a Blood-Brain Barrier Disruption. J Cereb Blood Flow Metab. 34(5):820-6.

Research Interest

Neurosurgery Neuro-oncology Neurology Nuclear Medicine and Radiobiology Pharmacology